<DOC>
	<DOCNO>NCT02205541</DOCNO>
	<brief_summary>The investigator aim perform first control randomize prospective study use ECZ pediatric STEC-HUS . This great interest still efficient specific therapy potentially devastating disease . Furthermore , publish data concern use ECZ STEC-HUS controversial , reflect statistical bias retrospective uncontrolled study , thus emphasize need prospective study .</brief_summary>
	<brief_title>Eculizumab Shiga-toxin Related Hemolytic Uremic Syndrome Pediatric Patients - ECULISHU</brief_title>
	<detailed_description>Hemolytic uremic syndrome ( HUS ) , characterize thrombocytopenia , hemolytic anemia acute renal failure ( ARF ) , mainly affect child young 5 year old . Shiga-toxin ( Stx ) relate HUS ( STEC-HUS ) due Stx secrete bacteria ( mainly enterohemorrhagic Escherichia Coli strain ) . Acute phase STEC-HUS severe least 50 % affected child require dialysis , 20 % present neurological involvement 5 % cardiac involvement . Mortality rate reach 5 % pediatric series long-term renal sequel report least 30 % survive patient . Apart supportive care , specific treatment ( plasma exchange ) proven efficacy life-threatening disease . Recently , activation complement alternative pathway ( CAP ) demonstrate STEC-HUS patient experimental study highlight Stx induce CAP activation human endothelial cell platelet-leucocytes complex , addition direct cell toxicity induce apoptosis , process end microvasculature thrombosis . CAP activation demonstrate cause atypical HUS ( aHUS ) ECZ , monoclonal C5 antibody , inhibit terminal complement complex ( TCC ) formation , efficiently prevent evolution end stage renal disease aHUS patient . In 2011 , Lapeyraque et al . report possible efficacy 3 severe STEC-HUS pediatric patient . Nevertheless , STEC-HUS , ECZ use uncontrolled study , mostly 2011 German outbreak , conflict result . Considering lack therapy prevent life-threatening complication renal sequel STEC-HUS logically expect efficacy ECZ , control study mandatory . In recruit center , STEC-HUS patient ARF propose enroll trial exception patient multiorgan . After parental consent , patient randomize receive either ECZ dextrose-based placebo single blind fashion . According patient body weight , 3 5 injection day ( D ) 0 , D7 , D14 , D21 D28 . According length initial hospital stay , patient may remain injection day ward recruit center . Dosage ECZ base previous trial use ECZ pediatric aHUS patient . We design single blind study patient treat placebo develop severe multiorgan involvement switch ECZ arm . ECZ placebo administrate intravenously 30-minute injection . In patient receive hemodialysis , ECZ injection perform dialysis session . Before first injection , patient receive tetravalent meningococcal vaccine oral antibiotic prophylaxis continue 14 day last injection . This single blind , phase III , randomize , multi-center control versus placebo clinical trial eculizumab STEC-HUS patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Shiga Toxins</mesh_term>
	<criteria>Pediatric patient ( 1 month18 year old ) Affected STECHUS define : Thrombocytopenia ( &lt; 150 000/mm3 ) Mechanic hemolytic anemia ( Hemoglobin &lt; 10g/dL , haptoglobin &lt; LLN , lactate dehydrogenase ( LDH ) &gt; upper limit normal ( ULN ) and/or bilirubin &gt; ULN , presence schizocytes ) ARF define estimate Schwartz 2009 creatinin clearance &lt; 75ml/min/1,73mÂ² With prodromal diarrhea and/or presence enterohemorrhagic strain Escherichia Coli and/or identification Stx 1 2 gene stool sample rectal swab Written consent 2 parent Female patient childbearing potential must practice effective , reliable medically acceptable contraceptive regimen entire duration study 5 month end participation . Neonatal HUS Malignancy Known HIV infection Pregnancy lactation Identified drug exposurerelated HUS Infectionrelated HUS Known systemic lupus erythematosus antiphospholipid antibody positivity syndrome Patient already enrol drug trial Patient ongoing meningococcal infection Patient affect aHUS family history aHUS STECHUS patient severe multiorgan involvement diagnostic : Neurological involvement ( seizure , coma , focal deficit ) sign microangiopathy cerebral Magnetic Resonance Imaging . Cardiac involvement ( cardiac failure , ischemic myocarditis , conduction rhythm trouble ) Digestive involvement ( severe pancreatitis define lipasemia &gt; 500UI/L , severe hepatitis define transaminase &gt; x10ULN and/or prothrombin time &lt; 60 % , hemorrhagic colitis , bowel perforation , rectal prolapsus )</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Eculizumab</keyword>
	<keyword>Shiga-toxin</keyword>
	<keyword>hemolytic uremic syndrome</keyword>
	<keyword>pediatric</keyword>
</DOC>